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Purpose: To investigate the toxicity of nelfinavir, administered during preoperative chemoradiotherapy
(CRT) in patients with locally advanced rectal cancer.
Material and methods: Twelve patients were treated with chemoradiotherapy to 50.4 Gy combined with
capecitabine 825 mg/m2 BID. Three dose levels (DL) of nelfinavir were tested: 750 mg BID (DL1), 1250 mg
BID (DL2) and an intermediate level of 1000 mg BID (DL3). Surgery was performed between 8 and
10 weeks after completion of CRT. Primary endpoint was dose-limiting toxicity (DLT), defined as any
grade 3 or higher non-hematological or grade 4 or higher hematological toxicity.
Results: Eleven patients could be analyzed: 5 were treated in DL1, 3 in DL2 and 3 in DL3. The first 3
patients in DL1 did not develop a DLT. In DL2 one patient developed gr 3 diarrhea, 1 patient had gr 3
transaminase elevation and 1 patient had a gr 3 cholangitis with unknown cause. An intermediate dose
level was tested in DL3. In this group 2 patients developed gr 3 diarrhea and 1 patient gr 3 transaminase
elevation and gr 4 post-operative wound complication. Three patients achieved a pathological complete
response (pCR).
Conclusions: Nelfinavir 750 mg BID was defined as the recommended phase II dose in combination with
capecitabine and 50.4 Gy pre-operative radiotherapy in rectal cancer. First tumor response evaluations
are promising, but a further phase II study is needed to get more information about efficacy of this treat-
ment regimen.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013) 184–188Pre-operative radiotherapy plays an important role in the treat-
ment of rectal cancer. It improves local control and may increase
the chance of sphincter-saving surgery [1,2] and is often combined
with chemotherapy to enhance the effect of radiotherapy [3]. The
most frequently used combination is 5-fluorouracil or capecitabine
and radiotherapy to doses around 45–50.4 Gy, resulting in patho-
logical complete response (pCR) rates of 10–33%, depending on
radiation dose and the interval between completion of treatment
and surgery [4–6]. Patients who develop a complete response have
a better prognosis [7,8] and may be candidates for less invasive
surgery or even a wait-and-see policy [9].
PI3Ks are frequently altered in human colorectal cancers [10–
13] and the PI3K signaling pathway can be constitutively activated
in colorectal cancer [14]. As PI3K mutations seem to be common in
colorectal cancer, inhibition of the PI3K pathway may well be abled Ltd. All rights reserved.
ic, P.O. Box 1345, 6201 BH
en).to influence the response to radiation. However, up until now, no
clinically usable PI3K inhibitors have been available.
HIV protease inhibitors (HPIs) are a group of drugs that have
been used for more than a decade in the treatment of HIV as part
of highly active anti-retroviral therapy (HAART). HPIs have been
shown to possess anti-tumor activity that is independent of their
anti-retroviral activity and to have a radiosensitizing effect
through the inhibition of phosphorylated-Akt (pAKT) [15]. The
inhibition of PI3K during radiotherapy is not expected to result
in increased normal tissue toxicity because this pathway is not
constitutively activated in normal cells. No specific pre-clinical
data are available for colorectal cancer cells, but it has been shown
in vitro that inhibition of the PI3K/Akt pathway leads to radiosen-
sitization of different cell lines in vitro and in vivo, including colon
cancer, bladder cancer and glioma cell lines [16–18]. Therefore, we
hypothesized that the addition of an HPI to chemoradiation for rec-
tal cancer would increase the effect of treatment, resulting in a
higher percentage of pCR. Due to the extensive clinical experience
with HPIs in HIV treatment, they form an interesting group of Akt
inhibitors to test in clinical practice. The HPI nelfinavir was the
Table 1
Patient characteristics.



















J. Buijsen et al. / Radiotherapy and Oncology 107 (2013) 184–188 185most potent inhibitor of the PI3K-Akt pathway in pre-clinical stud-
ies. In HAART therapy it is prescribed in a dose of 1250 mg BID and
the most commonly observed side-effects are diarrhea (>10%) and
transaminase elevations (around 2%) and nausea.
Since there is room for improvement in the number of pCRs, we
felt it was worthwhile to set up a phase I trial testing the combina-
tion of different nelfinavir dose levels with capecitabine and radio-
therapy. The primary endpoint was to evaluate the toxicity of this
combined modality treatment in order to find the recommended
phase II dose (RP2D).
Patients, materials, and methods
The aim of this phase I study was to define the RP2D of nelfina-
vir in combination with capecitabine 825 mg/m2 and radiotherapy
in patients with cT3-4N0-2M0 (staging based on MRI) rectal can-
cer. Two dose levels (DLs 1 and 2) of nelfinavir were planned to test
with the possibility of exploring an intermediate DL3 if DL2 turned
out to be too toxic: 750 mg BID (DL1), 1250 mg BID (DL2) and
1000 mg BID (DL3). Nelfinavir plasma levels were monitored in
weeks two, four and six, using an HPLC-UV method [19]. To correct
for the different timepoints at which samples for drug level mea-
surement were taken, the drug concentration ratio (CR) was calcu-
lated for each sample [20] by dividing the drug concentration
measured in that sample by the time-adjusted value in the stan-
dardized pharmacokinetic curve. Nelfinavir doses were adjusted
if CRs were lower than 0.90 or higher than 1.5. Dose limiting tox-
icity was defined as any grade 3 or more non-hematologic toxicity,
any grade 4 or more hematologic toxicity or any grade 4 or higher
post-operative toxicity within 30 days post-surgery (NCI-CTCAE
v3.0). Surgical resection was performed preferably between eight
to ten weeks after the end of CRT. Patients who had node-positive
disease received adjuvant chemotherapy (capacitabine/oxalipla-
tin). According to the protocol of the referring hospital, 1 or 2 cy-
cles could be administered in the interval between the
completion of CRT and resection.
Tumor regression grade (TRG) was scored by one pathologist
according to the Mandard scoring system [21]. In short, scores ran-
ged from TRG5 (no changes) to TRG1 (no viable tumor cells left).
The primary objective of this study was to evaluate the safety of
nelfinavir, capecitabine and radiotherapy and to identify the RP2D
of nelfinavir among patients with locally advanced rectal cancer. A




Twelve patients (five DL1, three DL2 and four DL3) were en-
rolled in the study between October 2008 and September 2010.
One patient in DL3 had no measurable nelfinavir levels at all time-
points. Although he affirmed that he took the medication as pre-
scribed, we decided to exclude this patient from further analysis
and include an extra patient in DL2 since we judged this patient
to be unrepresentative for toxicity analysis. Therefore only 11 pa-
tients were analyzed. Patient characteristics are shown in Table 1.Toxicities
The first three DL1 patients did not experience any DLT. In DL2,
one patient developed a grade 3 transaminase elevation (without
clinical signs), and one patient had a grade 3 cholangitis for which
no specific cause could be found. Therefore, a relationship with the
treatment regimen could not be ruled out. In both patients, symp-
toms disappeared and lab values normalized after nelfinavir wasstopped. Radiotherapy treatment could be completed and both
events were graded as DLT. The third patient had grade 2 diarrhea
and developed a grade 3 ileus caused by excessive use of lopera-
mide. This grade 3 toxicity was considered to be at most indirectly
related to the use of nelfinavir. Radiotherapy had to be interrupted
and stopped after 32.4 Gy in this case.
Because 2/3 patients developed DLT, DL2 was deemed too toxic
and DL1 was expanded with another two patients, who did not
experience any toxicity Pgrade 3. Therefore an intermediate nelfi-
navir dose was explored in DL3. At this dose level 2/3 patients were
hospitalized for grade 3 diarrhea. Radiotherapy could be completed
in both patients. The third patient showed a grade 3 transaminase
elevation, again without clinical symptoms, which normalized
after stopping nelfinavir and he developed a grade 4 wound com-
plication of the abdominal wound for which surgical revision
was necessary. Although a relationship between this wound com-
plication and the study medication seems to be unlikely, it cannot
be ruled out completely. Because DLT occurred in all three patients
in DL3, DL1 was declared the MTD. An overview of all toxicities
Pgrade 3 is shown in Table 2. As can be concluded from the overall
treatment times (OTT) mentioned in this table, a treatment inter-
ruption of more than five days was necessary for one patient.Nelfinavir plasma levels
Nelfinavir plasma levels turned out to be quite variable be-
tween patients. In our patient group we observed mainly high
CRs: the median CRs were 1.7 (range 1.2–7.1), 1.2 (0.6–6.0) and
1.7 (1.1–4.1), respectively in weeks two, four and six of nelfinavir
use. In four patients (three in DL2 and one in DL3), the prescribed
nelfinavir dose was adapted because of CRs >1.5. All patients who
needed a dose adjustment also developed a DLT. In total 4/6 pa-
tients with DLT also had a CR >1.5. No clear relationship between
the height of CR and the occurrence of DLT was observed.Resections, response and follow-up
All patients underwent a radical resection. The mean interval
between radiotherapy and surgery was 67 days (range: 49–
112 days). Table 3 shows the responses of all patients. Three pa-
tients (27%) showed a pathological complete response. These pCRs
were all observed in DL2 and 3. Taking TRG into account and con-
sidering TRG1 and 2 to be good responders, four patients had a
good response (TRG1 and 2). T-downstaging was found in five
Table 2
Acute toxicity during chemoradiation until 4 weeks post-surgery.
Patient noa Dose level NFV Toxicity = gr 3 Dose adjustment NFVb Description Relation with study medication
1 750 mg BID n n
2 750 mg BID n n
3 750 mg BID n n
7 750 mg BID n n
8 750 mg BID n n
9 1000 mg BID y y grade 3 transaminase elevation
grade 4 wound dehiscence
Likely
Unlikely
10 1000 mg BID y y grade 3 diarrhea Possible
11 1000 mg BID y y grade 3 diarrhea Possible
4 1250 mg BID y n grade 3 ileus Indirectly
5 1250 mg BID y n grade 3 transaminase elevation Likely
6 1250 mg BID y y grade 3 cholangitis Possible
a In chronological order of inclusion in the trial.
b Dose adjustment due to high plasma levels.
Table 3






















1 750 mg BID y 50.4 37 n 58 APR cT3N2 ypT1N0 2
2 750 mg BID y 50.4 37 y, 2 76 LAR cT3N2 ypT3N0 3
3 750 mg BID y 50.4 37 y, 1 58 APR cT2N2 ypT3N2 4
7 750 mg BID y 50.4 39 n 49 APR cT3N0 ypT3N0 3
8 750 mg BID y 50.4 38 n 59 APR cT3N1 ypT3N0 3
9 1000 mg BID y 50.4 38 n 58 APR cT3N1 ypT0N0 1
10 1000 mg BID n 50.4 37 y, 2 71 LAR cT4N2 ypT0N0 1
11 1000 mg BID n 50.4 53 n 63 APR cT2N1 ypT2N0 4
4 1250 mg BID n 32.4 23 n 112 LAR cT3N2 ypT3N0 5
5 1250 mg BID n 50.4 37 n 63 LAR cT3N1 ypT0N0 1
6 1250 mg BID n 50.4 40 n 72 LAR cT3N0 ypT2N0 3
a Adjuvant chemotherapy given before surgery and if yes number of cycles.
b TRG scores according to Mandard.
186 Nelfinavir and chemoradiation in rectal cancer(45%) patients and N-downstaging in eight (73%) patients. At the
time of analysis, all patients were alive without local or distant
recurrence with a follow-up between five and 27 months.Discussion
This study demonstrates that the combination of capecitabine,
radiotherapy and nelfinavir is feasible, although the RP2D in this
combination turned out to be the lowest dose level tested
(750 mg BID). This is the third phase I study evaluating the use
of a protease inhibitor in combination with chemotherapy and
radiotherapy and the first study in rectal cancer patients. The other
studies evaluated pancreatic cancer and non-small cell lung cancer
patients [23,24]. In these studies, nelfinavir was added to radio-
therapy combined with gemcitabine and cisplatin in the pancreas
trial and radiotherapy and cisplatinum and etoposide in the lung
trial. In contrast to our observations, no DLT related to the study
medication was observed in both studies, which may be explained
by the different chemotherapies used in both studies and the dif-
ferent toxicity profiles of radiation of the upper abdomen versus
the pelvic region.
In this study design we chose to escalate the dose of nelfinavir
because the combination of radiotherapy and capecitabine in a
dose of 825 mg/m2 is already well established and widely used.
Diarrhea is a well-known side effect of this treatment regimen.
In a recent series of patients treated with radiotherapy and capecit-
abine, severe diarrhea (grade 3) was observed in 10.2% of patients
[25]. Furthermore, diarrhea has been reported in up to 50% of pa-
tients treated with capecitabine monotherapy, of which 15% wasclassified as severe diarrhea [26]. Because diarrhea is also a fre-
quently occurring side effect of nelfinavir [27], we decided to start
with a relatively low dose (750 mg BID) of this drug. In pre-clinical
studies, nelfinavir has been tested at concentrations normally
achieved in HIV positive patients treated with HAART and it has
been shown that higher doses only slightly increased radiation re-
sponse. Therefore, the dose used in HIV treatment (1250 mg BID)
was used as the highest dose level.
Diarrhea was observed frequently in this study. Severe diarrhea
(Pgrade 3) was only observed in DL2 and DL3. Patients who have a
deficiency in dihydropyrimidine dehydrogenase (DPD), an impor-
tant enzyme in the metabolism of 5-FU of which capecitabine is
a prodrug, can develop severe toxicity during capecitabine use.
Although patients in this study were not tested for DPD deficiency,
we had no clinical suspicion of such a deficiency as these patients
often develop severe toxicity of multiple organ systems, including
a very pronounced mucositis, early during treatment.
It was quite remarkable that two patients showed grade 3
transaminase elevations and one patient developed a grade 3 cho-
langitis. All patients in this study had normal liver function tests
before start of treatment. In trials testing nelfinavir for treatment
of HIV, the reported incidence of transaminase elevations was
around 2%, thus it is not a frequently occurring side effect [28].
Although elevated liver enzymes are reported frequently (1–10%)
during capecitabine monotherapy according to the product infor-
mation, this side effect is often mild and seldom a reason for dose
adjustments [26].
Hepatotoxicity has also been described with the use of HPIs,
though the reported rate of severe hepatotoxicity differs between
different HPIs. None of the patients in this study had a pre-existing
J. Buijsen et al. / Radiotherapy and Oncology 107 (2013) 184–188 187liver disease. In a meta-analysis including four studies looking at
hepatotoxicity, nelfinavir showed the lowest rate of transaminase
elevations as compared to other HPIs [28]. No additive effect of li-
ver toxicity between capecitabine and nelfinavir was described in
the literature. It is not clear whether the case of cholangitis was
treatment related, but no other clear cause could be found. There-
fore a relationship with the study drug could not be ruled out.
One of the downsides of nelfinavir is that plasma levels can vary
importantly between patients and that there is an interaction with
a broad group of drugs [29]. In the treatment of HIV patients, con-
centration ratios <0.90 are frequently observed [20]. In our patient
group, we mainly observed CRs that were higher than expected:
the dose adjustments were all results of too-high plasma levels.
Four out of six patients who developed DLT also needed a dose
adjustment of NFV because of high plasma levels. Although the
most important P450 isoenzymes in the metabolism of nelfinavir
are CYP3A and CYP2C19, CYP2C9 is also involved. Capecitabine is
an inhibitor of CYP2C9. This could be a possible explanation of
the relative high nelfinavir plasma levels requiring dose adjust-
ments. In an important part of the Caucasian population polymor-
phisms of CYP2C19 and CYP2C9 have been described [30]. These
polymorphisms can also lead to a different metabolism. Another
possible explanation could be a different absorption of nelfinavir
due to mucosa changes in the gastrointestinal tract caused by nel-
finavir. From the experience in HIV treatment no connection be-
tween high plasma levels and toxicity has been described.
Although our observations indicate a possible relationship be-
tween high NFV plasma levels and toxicity, the number of patients
in this phase I trial is too small to draw conclusions.
Three of 11 patients (27%) had a pathological complete response
and four of 11 patients (36%) had a major response taking TRG into
account. Although the response rate was rather high (27% pCR and
36% major response) compared to response rates reported in trials
using a comparable chemoradiation regimen [7], no conclusions
can be drawn about the additive effect of nelfinavir because of
the small sample.
The radiosensitizing effects of HPIs have been attributed to sev-
eral mechanisms: inhibition of Akt phosphorylation [15], protea-
some inhibition, the inhibition of matrix metalloproteinases and
immunomodulatory effects [31], as well as stimulation of apopto-
sis and autophagy [32] and improvement of vascular flow and de-
crease of hypoxia [33,34]. In combination with radiation, HPIs have
effects on endothelial cells, leading to increased apoptosis of endo-
thelial cells and blockage of endothelial cell migration and organi-
zation [35]. It is important to note that these mechanisms occur at
different nelfinavir concentrations in laboratory studies.
In conclusion, this study shows that the combination of nelfina-
vir with capecitabine-based chemoradiation in locally advanced
rectal cancer is feasible, but the toxicity rates are rather high. From
this phase I trial, nelfinavir 750 mg BID turned out to be the RP2D.
A further phase II study is needed to learn more about the safety
and efficacy of this combination treatment.
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